Research programme: antibacterials - Cantab Anti-infectives

Drug Profile

Research programme: antibacterials - Cantab Anti-infectives

Alternative Names: NVB333; Polymyxins

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novacta Biosystems
  • Developer Cantab Anti-infectives; Novacta
  • Class Peptides; Proteins
  • Mechanism of Action Cell wall inhibitors; Growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gram-negative infections
  • No development reported Gram-positive infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in United Kingdom (Parenteral)
  • 25 Jan 2016 Preclinical trials in Gram-negative infections in United Kingdom (unspecified route) before January 2016
  • 06 Jul 2009 Preclinical trials in Gram-positive infections in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top